Dr. Bradley Monk graduated at the top of his class from the University of Arizona College of Medicine in 1988, and completed a residency in obstetrics and gynecology at the University of California, Los Angeles, in 1992. Between 1988 and 1995, he was the recipient of three fellowships in medical genetics and gynecologic oncology. In 1995, Dr. Monk was appointed Director of Gynecologic Oncology at Texas Tech University Health Services Center and, from 1998 until recently, was Associate Professor of the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology at the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center and Director of Research in the Department of Obstetrics and Gynecology. Dr. Monk is currently Professor and Director in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. Dr. Monk is also a Professor on the Clinical Scholar Track at the University of Arizona College of Medicine – Phoenix. Dr. Monk’s research interests include chemotherapy to treat ovarian and cervical carcinoma; the etiology, biomarkers in gynecologic cancers; and quality of life in women with advanced ovarian cancer. He was the first to report the activity of anti-vascular growth factor (VEGF) therapy in ovarian cancer and his paper in the New England Journal of Medicine led to the global approval of anti-VEGF therapy in recurrent cervical cancer. He was also the lead author on the pivotal trial of trabectedin in recurrent ovarian cancer as well as many other studies that have met their primary endpoints. Dr. Monk was also awarded the highly prestigious Ernst Wertheim Award for his research in cervical cancer and is on the Board of Directors for the GOG Foundation, Inc. and is the Cervix Chair for NRG Oncology. Dr. Monk is a fellow of the American College of Surgeons (ACS), the American College of Obstetricians and Gynecologists (ACOG) and the American Society for Colposcopy and Cervical Pathology (ASCCP), as well as being an active member of the Society of Gynecologic Oncology (SGO), American Society of Clinical Oncology (ASCO) and other professional organizations. He has authored more than 235 peer-reviewed articles along with 30 book chapters dealing predominantly with the prevention and chemotherapy of gynecologic malignancies and patient quality of life.